SGRY · Surgery Partners, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGRY
this stock
Surgery Partners, Inc.
|
$1.88B | -6.9% | +19.3% | — | 9.9% |
|
HCA
HCA Healthcare, Inc.
|
$94.71B | -8.6% | +7.1% | 14.7 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.49B | -8.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.23B | +32.7% | +0.9% | 10.2 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.01B | +14.7% | +10.5% | 19.8 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGRY | +1.5% | -5.3% | +21.9% | +3.5% | -6.9% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +2.6% | -3.6% | +4.0% | +3.9% | -19.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.